Investor Presentation Q1 2023

145 Investor presentation First three months of 2023 Novo NordiskⓇ 2022 statement of ESG performance Environmental performance Resources Energy consumption for operations (1,000 GJ) Share of renewable power for production sites Water consumption for production sites (1,000 m³) Breaches of environmental regulatory limit values Emissions and waste Scope 1 emissions (1,000 tonnes) 2022 2021 2020 3,677 3,387 3,191 100% 100% 100% 3,918 3,488 3,368 75 12 15 76 77 75 Scope 2 emissions (1,000 tonnes) 16 16 15 Scope 3 emissions (1,000 tonnes)1 2,041 NA NA Waste from production sites (tonnes) 213,505 180,806 140,783 Patients Patients reached with Novo Nordisk's Diabetes care products (estimate in millions) 36.3 34.6 - Hereof reached via the Novo Nordisk Access to Insulin Commitment (estimate in millions)² 1.8 1.7 32.8 3.2 - Hereof children reached through Changing Diabetes® in Children (cumulative) People & employees 41,033 31,846 28,296 Employees (total) 55,185 48,478 45,323 88 Social performance Employee turnover Sustainable Employer Score³ Frequency of occupational accidents (number per million working hours) Gender in leadership positions (ratio men:women) Gender in senior leadership positions (ratio men:women) Gender in the Board of Directors (ratio men:women) Societies Total tax contribution (DKK million) Donations and other contributions (DKK million) 8.2% 11.0% 7.9% 85% 84% N/A 1.5 1.3 1.3 56:44 57:43 59:41 61:39 64:36 65:35 54:46 67:33 62:38 36,003 32,593 26,376 126 92 158 Change in average list price across US product portfolio (% change to previous year) Change in average net price across US product portfolio (% change to previous year) 2.4% 1.6% 2.3% -12.7% -12.3% Governance Performance Change in average list price across US insulin portfolio (% change to previous year) Change in average net price across US insulin portfolio (% change to previous year) Governance processes Business ethics reviews Employees trained in business ethics Supplier audits Product recalls Failed inspections Values and trust Facilitations of the Novo Nordisk Way Company reputation (scale 0-100)4 Animals purchased for research 1.2022 is the first year of full Scope 3 emissions' disclosure, which in 2020 and 2019 was limited to business flights and product distribution. 2. In 2020, the ceiling price was lowered from USD 4 to USD 3 which affects the comparability of 2021 and prior years 3. In 2021, the engagement survey was entirely redesigned to support Novo Nordisk's strategic goals. As a result, comparison to previous surveys is not appropriate. 4. In 2021, Company reputation replaced Company trust in order to capture more dimensions of how Novo Nordisk is perceived by external stakeholders. 0.0% 0.0% -19.5% -10.9% -16.9% 0.5% -26.9% 35 37 32 99% 98% 99% 294 253 177 3 1 0 0 0 0 36 82.3 79,750 34 82.6 47,879 26 N/A 50,036

View entire presentation